Portola Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PTLA)

$47.02 -0.53 (-1.11 %)
(As of 12/17/2017 12:46 PM ET)
Previous Close$47.02
Today's Range$46.33 - $48.09
52-Week Range$18.30 - $67.10
Volume1.46 million shs
Average Volume646,193 shs
Market Capitalization$3.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio0.24%
Current Ratio8.31%
Quick Ratio8.31%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.50 million
Price / Sales86.42
Cash FlowN/A
Price / CashN/A
Book Value$3.41 per share
Price / Book13.79

Profitability

Trailing EPS($4.32)
Net Income$-269,040,000.00
Net Margins-938.19%
Return on Equity-110.46%
Return on Assets-61.18%

Miscellaneous

Employees163
Outstanding Shares65,250,000

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.08. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. Portola Pharmaceuticals's quarterly revenue was down 58.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.64) earnings per share. View Portola Pharmaceuticals' Earnings History.

When will Portola Pharmaceuticals make its next earnings announcement?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Portola Pharmaceuticals.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued twelve-month target prices for Portola Pharmaceuticals' stock. Their forecasts range from $70.00 to $81.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $75.67 in the next year. View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (8/8/2017)
  • 2. Cowen Inc analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board (Age 70)
  • William Lis, Chief Executive Officer, Director (Age 52)
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President (Age 53)
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development (Age 65)
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer (Age 45)
  • John Lawrence, Senior Vice President, Chief Medical Officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director (Age 56)
  • Laura A. Brege, Independent Director (Age 59)
  • Dennis M. Fenton Ph.D., Independent Director (Age 65)
  • Charles J. Homcy M.D., Independent Director (Age 68)

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.29%), Kornitzer Capital Management Inc. KS (1.13%), Zevenbergen Capital Investments LLC (1.00%), Sectoral Asset Management Inc (0.78%), Pinnacle Associates Ltd. (0.75%) and Pictet Asset Management Ltd. (0.83%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., OxFORD Asset Management LLP, EAM Investors LLC, First Trust Advisors LP, Nicholas Investment Partners LP, Marcus Capital LLC, Hanseatic Management Services Inc. and New York State Common Retirement Fund. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Zevenbergen Capital Investments LLC, Sphera Funds Management LTD., Sectoral Asset Management Inc, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Chicago Equity Partners LLC and Prudential Financial Inc.. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $47.02.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $3.07 billion and generates $35.50 million in revenue each year. The biopharmaceutical company earns $-269,040,000.00 in net income (profit) each year or ($4.32) on an earnings per share basis. Portola Pharmaceuticals employs 163 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Portola Pharmaceuticals (NASDAQ:PTLA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.882.882.88
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $75.67$67.67$65.83$40.83
Price Target Upside: 53.70% upside33.86% upside10.66% upside16.47% upside

Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History

Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017OppenheimerSet Price TargetBuy$80.00LowView Rating Details
12/1/2017Goldman Sachs GroupInitiated CoverageBuy -> Buy$75.00HighView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$75.00 -> $81.00N/AView Rating Details
8/23/2017Credit Suisse GroupUpgradeNeutral -> Outperform$70.00HighView Rating Details
6/26/2017CowenBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/26/2017CitigroupBoost Price TargetBuy$51.00 -> $78.00MediumView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($1.33)N/AView Earnings Details
11/6/2017Q3 2017($1.49)($1.41)$4.71 million$3.83 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates

2017 EPS Consensus Estimate: ($5.52)
2018 EPS Consensus Estimate: ($2.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.24)($1.06)($1.15)
Q3 20172($1.68)($1.45)($1.57)
Q4 20172($1.67)($1.52)($1.60)
Q1 20182($1.04)$0.07($0.49)
Q2 20182($1.20)($0.85)($1.03)
Q3 20182($1.01)($0.57)($0.79)
Q4 20182($0.94)($0.23)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 87.45%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.70View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Portola Pharmaceuticals (NASDAQ PTLA) News Headlines

Source:
DateHeadline
Portola Pharmaceuticals Inc (PTLA) Expected to Announce Earnings of -$1.52 Per SharePortola Pharmaceuticals Inc (PTLA) Expected to Announce Earnings of -$1.52 Per Share
www.americanbankingnews.com - December 16 at 9:24 PM
Oppenheimer Research Analysts Lower Earnings Estimates for Portola Pharmaceuticals Inc (PTLA)Oppenheimer Research Analysts Lower Earnings Estimates for Portola Pharmaceuticals Inc (PTLA)
www.americanbankingnews.com - December 15 at 11:24 PM
Notable Two Hundred Day Moving Average Cross - PTLANotable Two Hundred Day Moving Average Cross - PTLA
www.nasdaq.com - December 14 at 5:04 PM
Portola Pharma (PTLA) Announces CHMP of EMA Requested Additional Information Related to MAA for BetrixabanPortola Pharma (PTLA) Announces CHMP of EMA Requested Additional Information Related to MAA for Betrixaban
www.streetinsider.com - December 13 at 4:44 PM
Portola Pharmaceuticals (PTLA) PT Set at $80.00 by OppenheimerPortola Pharmaceuticals (PTLA) PT Set at $80.00 by Oppenheimer
www.americanbankingnews.com - December 13 at 11:50 AM
Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : December 13, 2017Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : December 13, 2017
finance.yahoo.com - December 13 at 10:44 AM
Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for BetrixabanPortola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban
finance.yahoo.com - December 12 at 10:49 AM
Portola Pharmaceuticals Inc (PTLA) Given Consensus Rating of "Buy" by AnalystsPortola Pharmaceuticals Inc (PTLA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 8 at 10:00 PM
Portola Pharmaceuticals (PTLA) Rating Lowered to Strong Sell at BidaskClubPortola Pharmaceuticals (PTLA) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 7 at 11:14 PM
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - December 6 at 10:40 AM
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - NasdaqPortola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nasdaq
www.nasdaq.com - December 5 at 4:30 PM
Portola Pharmaceuticals: Does This 2017 Winner Still Have ROTY Potential? - Seeking AlphaPortola Pharmaceuticals: Does This 2017 Winner Still Have ROTY Potential? - Seeking Alpha
seekingalpha.com - December 5 at 4:30 PM
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 5 at 4:30 PM
$2.42 Million in Sales Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter$2.42 Million in Sales Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter
www.americanbankingnews.com - November 30 at 6:50 PM
Portola Pharma (PTLA) to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at ASHPortola Pharma (PTLA) to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at ASH
www.streetinsider.com - November 30 at 4:32 PM
Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual MeetingPortola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 30 at 11:01 AM
Zacks: Analysts Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.52 EPSZacks: Analysts Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.52 EPS
www.americanbankingnews.com - November 28 at 5:20 PM
Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : November 27, 2017Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : November 27, 2017
finance.yahoo.com - November 27 at 4:29 PM
ETFs with exposure to Portola Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to Portola Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 4:29 PM
Portola Shares Lower After Update on Anticoagulant Launch -- Biotech MoversPortola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers
finance.yahoo.com - November 23 at 7:51 AM
Why this doctor returned to Genentech to give hemophilia patients a shotWhy this doctor returned to Genentech to give hemophilia patients a shot
www.bizjournals.com - November 22 at 4:25 AM
Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch - GlobeNewswire (press release)Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch - GlobeNewswire (press release)
globenewswire.com - November 21 at 11:23 PM
Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial LaunchPortola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch
finance.yahoo.com - November 21 at 11:23 PM
Portola shares slip as FDA review pushes possible drug release to FebruaryPortola shares slip as FDA review pushes possible drug release to February
finance.yahoo.com - November 21 at 11:23 PM
Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 21 at 9:35 AM
Portola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of "Buy" from AnalystsPortola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 10:06 PM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Post Quarterly Sales of $2.42 MillionPortola Pharmaceuticals, Inc. (PTLA) Expected to Post Quarterly Sales of $2.42 Million
www.americanbankingnews.com - November 11 at 2:10 AM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Announce Earnings of -$1.60 Per SharePortola Pharmaceuticals, Inc. (PTLA) Expected to Announce Earnings of -$1.60 Per Share
www.americanbankingnews.com - November 9 at 11:04 PM
Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?
seekingalpha.com - November 9 at 11:57 AM
Portola Pharmaceuticals, Inc. to Post FY2017 Earnings of ($5.07) Per Share, Oppenheimer Holdings Forecasts (PTLA)Portola Pharmaceuticals, Inc. to Post FY2017 Earnings of ($5.07) Per Share, Oppenheimer Holdings Forecasts (PTLA)
www.americanbankingnews.com - November 9 at 7:21 AM
FY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Decreased by William BlairFY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Decreased by William Blair
www.americanbankingnews.com - November 9 at 7:21 AM
Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)
www.americanbankingnews.com - November 8 at 10:44 PM
Portola Pharmaceuticals, Inc. (PTLA) Expected to Earn FY2019 Earnings of $1.11 Per SharePortola Pharmaceuticals, Inc. (PTLA) Expected to Earn FY2019 Earnings of $1.11 Per Share
www.americanbankingnews.com - November 8 at 9:52 PM
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the ... - NasdaqPortola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the ... - Nasdaq
www.nasdaq.com - November 7 at 9:10 AM
Portola Pharmaceuticals (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaPortola Pharmaceuticals' (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 7 at 9:10 AM
Portola Pharmaceuticals, Inc. to Host Earnings CallPortola Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical OfficerPortola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdatePortola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals posts 3Q lossPortola Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 7 at 9:10 AM
Edited Transcript of PTLA earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of PTLA earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017
finance.yahoo.com - November 7 at 9:10 AM
Portola Pharmaceuticals, Inc. (PTLA) Announces Quarterly  Earnings Results, Beats Estimates By $0.08 EPSPortola Pharmaceuticals, Inc. (PTLA) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - November 6 at 9:24 PM
Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 4 at 9:23 AM
Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare ConferencePortola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 4 at 9:23 AM
Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday ... - GlobeNewswire (press release)Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday ... - GlobeNewswire (press release)
globenewswire.com - October 31 at 8:16 AM
Portola Pharmaceuticals, Inc. (PTLA) Scheduled to Post Quarterly Earnings on MondayPortola Pharmaceuticals, Inc. (PTLA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
Commit To Purchase Portola Pharmaceuticals At $40, Earn 17.2% Annualized Using Options - NasdaqCommit To Purchase Portola Pharmaceuticals At $40, Earn 17.2% Annualized Using Options - Nasdaq
www.nasdaq.com - October 27 at 11:56 AM
 Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Post Quarterly Sales of $2.42 Million Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Post Quarterly Sales of $2.42 Million
www.americanbankingnews.com - October 23 at 11:54 AM
Portola Pharmaceuticals, Inc. (PTLA) Receives Average Recommendation of "Buy" from BrokeragesPortola Pharmaceuticals, Inc. (PTLA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 19 at 6:50 PM
Portola Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($4.86) Per Share (PTLA)Portola Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($4.86) Per Share (PTLA)
www.americanbankingnews.com - October 13 at 7:54 AM

SEC Filings

Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.